Trial Profile
Phase II study of Iressa [gefitinib] in relapsed and refractory small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2008
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 26 Nov 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 24 Mar 2006 New trial record.